{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:28:00Z","timestamp":1779359280263,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100001063","name":"Crohn's and Colitis Foundation of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001063","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Health","award":["K23DK124570"],"award-info":[{"award-number":["K23DK124570"]}]},{"name":"National Institute of Health","award":["K23DK127157"],"award-info":[{"award-number":["K23DK127157"]}]},{"name":"Judith & Stewart Colton Center for Autoimmunity"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s10620-023-08044-7","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T05:01:53Z","timestamp":1691384513000},"page":"3596-3604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Suboptimal Guideline Adherence and Biomarker Underutilization in Monitoring of Post-operative Crohn\u2019s Disease"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-4763","authenticated-orcid":false,"given":"Terry","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Click","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salam","family":"Bachour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward L.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin L.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susell","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Axelrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"8044_CR1","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/ajg.2009.579","volume":"105","author":"L Peyrin-Biroulet","year":"2010","unstructured":"Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn\u2019s disease in population-based cohorts. Am J Gastroenterol. 2010;105:289\u2013297.","journal-title":"Am J Gastroenterol."},{"key":"8044_CR2","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1053\/j.gastro.2013.07.041","volume":"145","author":"AD Frolkis","year":"2013","unstructured":"Frolkis AD, Dykeman J, Negr\u00f3n ME et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145:996\u20131006.","journal-title":"Gastroenterology."},{"key":"8044_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1136\/gut.33.3.331","volume":"33","author":"G Olaison","year":"1992","unstructured":"Olaison G, Smedh K, Sj\u00f6dahl R. Natural course of Crohn\u2019s disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut. 1992;33:331\u2013335.","journal-title":"Gut."},{"key":"8044_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1053\/j.gastro.2016.10.038","volume":"152","author":"GC Nguyen","year":"2017","unstructured":"Nguyen GC, Loftus EV, Hirano I et al. American Gastroenterological Association Institute guideline on the management of Crohn\u2019s disease after surgical resection. Gastroenterology. 2017;152:271\u2013275.","journal-title":"Gastroenterology."},{"key":"8044_CR5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/2050640613501818","volume":"1","author":"T Yamamoto","year":"2013","unstructured":"Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn\u2019s disease after ileocolonic resection: a prospective pilot study. United Eur Gastroenterol J. 2013;1:368\u2013374.","journal-title":"United Eur Gastroenterol J."},{"key":"8044_CR6","doi-asserted-by":"crossref","first-page":"175628481878557","DOI":"10.1177\/1756284818785571","volume":"30","author":"YS Tham","year":"2018","unstructured":"Tham YS, Yung DE, Fay S et al. Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn\u2019s disease: systematic review and meta-analysis. Therapeutic Adv Gastroenterol. 2018;30:1756284818785571.","journal-title":"Therapeutic Adv Gastroenterol."},{"key":"8044_CR7","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1080\/00365521.2021.1955965","volume":"56","author":"C Primas","year":"2021","unstructured":"Primas C, Hopf G, Reinisch S et al. Role of fecal calprotection in predicting endoscopic recurrence in postoperative Crohn\u2019s disease. Scand J Gastroenterol. 2021;56:1169\u20131174.","journal-title":"Scand J Gastroenterol."},{"key":"8044_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cgh.2010.01.016","volume":"8","author":"D Sorrentino","year":"2010","unstructured":"Sorrentino D, Paviotti A, Terrosu G et al. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn\u2019s disease. Clin Gastroenterol Hepatol 2010;8:591\u2013599.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8044_CR9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/ajg.2015.30","volume":"110","author":"G Boschetti","year":"2015","unstructured":"Boschetti G, Moussata D, Stefanescu C et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn\u2019s disease. Am J Gastroenterol 2015;110:865\u2013872.","journal-title":"Am J Gastroenterol"},{"key":"8044_CR10","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1148\/radiol.09091165","volume":"254","author":"P Soyer","year":"2010","unstructured":"Soyer P, Boudiaf M, Sirol M et al. Suspected anastomotic recurrence of Crohn disease after ileocolic resection: evaluation with CT enteroclysis. Radiology. 2010;254:755\u2013764.","journal-title":"Radiology."},{"key":"8044_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/ibd.21003","volume":"16","author":"S Koilakou","year":"2010","unstructured":"Koilakou S, Sailer J, Peloschek P et al. Endoscopy and MR enteroclysis: equivalent tools in predicting clinical recurrence in patients with Crohn\u2019s disease after ileocolic resection. Inflamm Bowel Dis. 2010;16:198\u2013203.","journal-title":"Inflamm Bowel Dis."},{"key":"8044_CR12","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1053\/j.gastro.2022.01.024","volume":"162","author":"N Plevris","year":"2022","unstructured":"Plevris N, Lees CW. Disease monitoring in IBD: evolving principles and possibilities. Gastroenterology. 2022;162:1456.","journal-title":"Gastroenterology."},{"key":"8044_CR13","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","volume":"390","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Panaccione R, Bossuyt P et al. Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390:2779\u20132789.","journal-title":"Lancet."},{"key":"8044_CR14","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/ecco-jcc\/jjac077","volume":"16","author":"R Battat","year":"2022","unstructured":"Battat R. Serum monitoring of recurrence in post-operative Crohn\u2019s disease: have we arrived? J Crohn\u2019s Colitis. 2022;16:1795\u20131796.","journal-title":"J Crohn's Colitis."},{"key":"8044_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-3-030-11446-6_8","volume-title":"Biomarkers in inflammatory bowel diseases","author":"K Patwala","year":"2019","unstructured":"Patwala K, De Cruz P. Postoperative Crohn\u2019s disease. In: De Cruz P, ed. Cham: Springer; 2019; 89\u201397."},{"key":"8044_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000507115","volume":"5","author":"SR Vavricka","year":"2020","unstructured":"Vavricka SR, Greuter T, Br\u00fcngger B et al. Follow-up ileocolonoscopy is underused in Crohn\u2019s disease patients after ileocecal resection despite higher total and inpatient health-care costs compared to controls. Inflamm Intest Dis. 2020;5:100\u2013108.","journal-title":"Inflamm Intest Dis."},{"key":"8044_CR17","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1053\/j.gastro.2017.11.274","volume":"154","author":"DH Bruining","year":"2018","unstructured":"Bruining DH, Zimmermann EM, Loftus EV Jr et al. Consensus recommendations for evaluation, interpretation, and utilization of computed tomography and magnetic resonance enterography in patients with small bowel Crohn\u2019s disease. Gastroenterology. 2018;154:1172\u20131194.","journal-title":"Gastroenterology."},{"key":"8044_CR18","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/apt.16804","volume":"55","author":"SP Bachour","year":"2022","unstructured":"Bachour SP, Shah RS, Lyu R et al. Mild neoterminal ileal post-operative recurrence of Crohn\u2019s disease conveys higher risk for severe endoscopic disease progression than isolated anastomotic lesions. Aliment Pharmacol Ther. 2022;55:1139\u20131150.","journal-title":"Aliment Pharmacol Ther."},{"key":"8044_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ecco-jcc\/jjw169","volume":"11","author":"P Gionchetti","year":"2017","unstructured":"Gionchetti P, Dignass A, Danese S et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 2: surgical management and special situations. J Crohn\u2019s Colitis. 2017;11:135\u2013149.","journal-title":"J Crohn's Colitis."},{"key":"8044_CR20","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/S0140-6736(14)61908-5","volume":"385","author":"P De Cruz","year":"2015","unstructured":"De Cruz P, Kamm MA, Hamilton AL et al. Crohn\u2019s disease management after intestinal resection: a randomised trial. The Lancet. 2015;385:1406\u20131417.","journal-title":"The Lancet."},{"key":"8044_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012328.pub2","author":"R Candia","year":"2020","unstructured":"Candia R, Bravo-Soto GA, Monrroy H, Hernandez C, Nguyen GC. Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn\u2019s disease. Cochrane Database Syst Rev. 2020. https:\/\/doi.org\/10.1002\/14651858.CD012328.pub2.","journal-title":"Cochrane Database Syst Rev."},{"key":"8044_CR22","doi-asserted-by":"publisher","first-page":"11246","DOI":"10.3748\/wjg.v21.i40.11246","volume":"21","author":"S Chang","year":"2015","unstructured":"Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol. 2015;21:11246.","journal-title":"World J Gastroenterol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-08044-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-023-08044-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-08044-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T02:11:45Z","timestamp":1692756705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-023-08044-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["8044"],"URL":"https:\/\/doi.org\/10.1007\/s10620-023-08044-7","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]},"assertion":[{"value":"17 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jordan E. Axelrad reports research grants from BioFire Diagnostics; consultancy fees, honorarium, or advisory board fees from BioFire Diagnostics, Janssen, Pfizer, Bristol Myers Squibb, Adiso, and Abbvie. Terry Li reports no disclosures. Salam P. Bachour reports no disclosures. Michael C. Sachs reports no disclosures. Edward L. Barnes reports consulting for AbbVie, Gilead, Pfizer, and TARGET-RWE. Benjamin L. Cohen receives financial support for advisory boards and consultant for Abbvie, Celgene-Bristol Myers Squibb, Pfizer, Sublimity Therapeutics, Takeda, and TARGET-RWE; CME Companies: Cornerstones and Vindico; and Speaking: Abbvie. Benjamin Click reports consulting fees for IBD Education Group, TARGET-RWE, and Takeda. Susell Contreras reports no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The institutional review board approved this study at participating centers. All ethical principles laid out in the Declaration of Helsinki were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}